Pharming Group N.V. (FRA:PHG)
Germany · Delayed Price · Currency is EUR 16.70
-0.10 (-0.60%)
Last updated: Jan 28, 2026, 3:25 PM CET
Pharming Group Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 362.27 | 297.2 | 245.32 | 205.62 | 198.87 | 212.17 | |
Revenue Growth (YoY) | 26.78% | 21.15% | 19.30% | 3.40% | -6.27% | 12.03% |
Cost of Revenue | 36.58 | 35.4 | 25.21 | 17.56 | 21.14 | 23.54 |
Gross Profit | 325.7 | 261.8 | 220.1 | 188.06 | 177.73 | 188.64 |
Selling, General & Admin | 198.25 | 184.43 | 175.26 | 127.44 | 90.97 | 75.69 |
Research & Development | 88.43 | 83.15 | 68.66 | 52.53 | 65.38 | 38.52 |
Other Operating Expenses | -2.45 | -2.18 | -2.07 | -2.28 | -2.62 | -1.83 |
Operating Expenses | 284.24 | 265.4 | 241.85 | 177.69 | 153.73 | 112.38 |
Operating Income | 41.46 | -3.59 | -21.75 | 10.37 | 24 | 76.26 |
Interest Expense | -14.3 | -8.74 | -5.96 | -5.36 | -6.09 | -5.94 |
Interest & Investment Income | 2.85 | 4.86 | 3.66 | 0.09 | 0.05 | 0.72 |
Earnings From Equity Investments | -0.76 | -1.76 | -0.29 | -1.08 | 0.69 | 0.36 |
Currency Exchange Gain (Loss) | 1.99 | 1.99 | -2.97 | 4.4 | 14.84 | -19.23 |
Other Non Operating Income (Expenses) | -1.38 | 3.78 | -1.06 | -1.29 | -0.09 | -0.07 |
EBT Excluding Unusual Items | 29.85 | -3.47 | -28.38 | 7.12 | 33.4 | 52.08 |
Gain (Loss) on Sale of Investments | - | - | - | 12.24 | 0.11 | 0.07 |
Gain (Loss) on Sale of Assets | - | - | 21.28 | - | - | - |
Asset Writedown | -5.03 | -5.03 | -4.92 | -4.38 | -10.44 | - |
Other Unusual Items | - | - | - | - | - | -8.06 |
Pretax Income | 14.73 | -8.49 | -12.01 | 14.99 | 23.08 | 44.09 |
Income Tax Expense | 14.66 | 3.35 | -1.46 | 1.31 | 7.08 | 6.35 |
Net Income | 0.38 | -11.84 | -10.55 | 13.67 | 16 | 37.75 |
Net Income to Common | 0.38 | -11.84 | -10.55 | 13.67 | 16 | 37.75 |
Net Income Growth | - | - | - | -14.52% | -57.62% | -6.93% |
Shares Outstanding (Basic) | 635 | 671 | 657 | 649 | 642 | 636 |
Shares Outstanding (Diluted) | 635 | 671 | 657 | 707 | 701 | 683 |
Shares Change (YoY) | -2.65% | 2.18% | -7.09% | 0.85% | 2.70% | 1.37% |
EPS (Basic) | 0.00 | -0.02 | -0.02 | 0.02 | 0.02 | 0.06 |
EPS (Diluted) | 0.00 | -0.02 | -0.02 | 0.02 | 0.02 | 0.05 |
EPS Growth | - | - | - | -17.39% | -58.18% | -9.84% |
Free Cash Flow | 52.72 | -2.59 | -18.74 | 21.08 | 27.1 | 78.97 |
Free Cash Flow Per Share | 0.08 | -0.00 | -0.03 | 0.03 | 0.04 | 0.12 |
Gross Margin | 89.90% | 88.09% | 89.72% | 91.46% | 89.37% | 88.91% |
Operating Margin | 11.44% | -1.21% | -8.87% | 5.04% | 12.07% | 35.94% |
Profit Margin | 0.10% | -3.98% | -4.30% | 6.65% | 8.04% | 17.79% |
Free Cash Flow Margin | 14.55% | -0.87% | -7.64% | 10.25% | 13.63% | 37.22% |
EBITDA | 47.91 | 3.22 | -15.29 | 17.13 | 30.39 | 82.54 |
EBITDA Margin | 13.23% | 1.08% | -6.23% | 8.33% | 15.28% | 38.90% |
D&A For EBITDA | 6.46 | 6.82 | 6.46 | 6.76 | 6.39 | 6.29 |
EBIT | 41.46 | -3.59 | -21.75 | 10.37 | 24 | 76.26 |
EBIT Margin | 11.44% | -1.21% | -8.87% | 5.04% | 12.07% | 35.94% |
Effective Tax Rate | 99.53% | - | - | 8.76% | 30.69% | 14.40% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.